Introduction

The onset of inflammation is mediated by the secretion of chemokines, which initiate the immigration of leukocytes from circulation to the site of injury and infection. The canonical chemokine CXCL8 (IL-8) binds with high affinity to two highly homologous chemokine receptors CXCR1 and CXCR2, which mediate pleiotropic responses including the onset of inflammation, angiogenesis, wound healing and tumorigenesis [1]. Chemokines are folded into three antiparallel β-sheets and a α helix on the top, with an unstructured N-terminus containing the ELR triad [1]. Chemokines are postulated for the interactions of chemokines with their cognate extracellular loops of the receptor for binding to the N-terminus containing the ELR triad, and CXC motif which connects the ELR to the N-loop and the 30 s loop [2]. The functional significance of CXCR1 is the cross-talk between CXCR1 and CXCR2 in cells co-expressing both receptors, and their mechanisms of activation by CXCL8 and related ELR-CXC chemokines, are currently unknown. Whereas the functional role of CXCR2 can be examined by using CXCR2-deficient mice [3] or non-peptide CXCR2 antagonists [4], elucidating the role of CXCR1 in vivo is hampered by the lack of specific CXCR1 agonists and antagonists, and because mice and rat do not express CXCR1 in neutrophils and they do not express the human homologue of CXCL8 [5]. An argument is that CXCR1 is redundant; however the importance of CXCR1 was highlighted by studies suggesting that CXCR1 plays a significant role on the regulation and progression of chronic inflammatory disorders, including cystic fibrosis, COPD, and in sporadic urinary infections [6,7].

On the basis of numerous mutagenesis and structural studies of chemokines and their cognate receptors, a two-site model was postulated for the interactions of chemokines with their cognate receptors [8]. Site 1 includes the receptor N-terminus, which recognizes the N-loop of chemokines, and site 2 includes extracellular loops of the receptor for binding to the N-terminus of chemokines to trigger receptor activation. This model, however, fails to account for the selective interaction of CXCR1 with CXCL8, and the non-selective interactions of CXCR2 with all ELR-CXC-chemokines, including those chemokines containing transplanted ELR triads into the nonELR-CXCL4 or the pseudo ELR in MIF1α [9,10]. In this work, we have engineered CXCL8 derivatives via modifications in its N-terminus (ELR and CXC) and discovered novel CXCR1 agonists, which have allowed identifying the major interactions between ELR-CXC chemokines with their cognate receptors and probing the functional cross-talk between CXCR1 and CXCR2 in human neutrophils co-expressing both receptors.

Results

Engineering of CXCR1 Agonists

To identify the sites in CXCL8 responsible for binding to CXCR c engineered CXCL8 derivatives by residue substitutions or deletions in the N-terminus of CXCL8 spanning the ELR triad and CXC motif. We found that CXCL8 mutants with residue substitutions of Arg6 in the ELR triad failed to increase the
intracellular calcium in HL-60 cells expressing CXCR2 (Fig. 1) or in Jurkat cells expressing receptors for CXC or CC chemokines (data not shown). However, most of these CXCL8 mutants activated CXCR1, as demonstrated by the increase in intracellular calcium in HL-60 cells expressing CXCR1, according to the following agonist ranking His>Gly>Lys>Ala (Fig. 1, Fig S1). In contrast the CXCL8 mutant with Asp substitution in the Glu4 site of the ELR motif triggered weaker calcium responses than wild-type CXCL8 in HL-60 cells expressing CXCR1 or CXCR2 (data not shown), suggesting that Glu4 site is not important for the selective activation of receptor subtypes.

Dose-response analysis showed that the CXCL8 derivative (R6H-CXCL8) was a full CXCR1 agonist for calcium responses, although with a 13-fold higher EC_{50} than wild-type CXCL8 (Fig. 2A); moreover this mutant displaced the $^{125}$I-CXCL8 bound to CXCR1 but did not displace $^{125}$I-CXCL8- or $^{125}$I-CXCL1-bound to HL60 cells expressing CXCR2 (Fig. 2B, Fig S2). Similarly, the single residue deletion CXCL8 mutant CC-CXCL8 (CC replaced CXC) is also a selective full CXCR1 agonist but with a 100-fold higher EC_{50} than wild-type CXCL8 (R6H-CXCL8) was a full CXCR1 agonist for calcium responses, although with a 13-fold higher EC_{50} than wild-type CXCL8 (data not shown), suggesting that Glu4 site is not important for the selective activation of receptor subtypes.

These results showed for the first time the generation of selective CXCR1 agonists, but most importantly our data reveal that the N-terminus of CXCL8 contains the major determinants for the binding and activation of CXCR2 and binding to DARC, but not for CXCR1.

Functional significance of CXCR1

The CXCR1 agonists identified in assays with HL-60 cells expressing CXCR1 or CXCR2 were probed in human neutrophils, which co-express both receptors. As expected we found that CXCL8 induced increase of intracellular calcium in neutrophils treated or untreated with the CXCR2 antagonist SB225002 [4] (Fig. 4A and 4D), as CXCL8 activates both CXCR1 and CXCR2. In contrast, the CXCR2 agonist CXCL1 did not induce calcium responses in neutrophils treated with SB225002 (Fig. 4B and 4E). Of importance, the CXCR1 agonists R6H-CXCL8 triggered calcium responses in neutrophils untreated or treated with SB225002 (Fig. 4C and 4F), further validating the selective activation of CXCR1 by R6H-CXCL8. Similarly, the CXCR1 agonists R6K, R6G and CC-CXCL8 also elicited calcium responses in neutrophils treated with SB225002, although at higher concentrations than R6H-CXCL8 or CXCL8 (Fig 5).

To examine the functional interactions between CXCR1 and CXCR2 we probed the desensitization of calcium responses in neutrophils mediated by each receptor using the newly identified CXCR1 agonists (R6H-CXCL8 and CC-CXCL8). Both CXCR1 agonists R6H-CXCL8 and CC-CXCL8 desensitized the calcium responses mediated by the same agonists, as demonstrated by the lack of calcium response to a second agonist challenge (Fig. 5A and 5B). Interestingly, activation of CXCR1 by R6H-CXCL8 did not desensitize the calcium response to the CXCR2 agonist CXCL1, whereas CC-CXCL8 completely desensitized the responses to CXCL1 (Fig 5C and 5D), indicating that these two CXCR1 agonists trigger distinct desensitization signals. As controls, CC-CXCL8 did not desensitize the CXCR2-mediated calcium responses in HL-60 cells expressing only CXCR2 (Fig 5E and 5F). Together, these results show that CXCR1 can elicit signals to desensitize calcium responses mediated by CXCR2 in a unidirectional fashion, as CXCR2 activation does not desensitize the CXCR1 responses.

Figure 1. The R6H-CXCL8 mutant triggered calcium responses in HL-60 cells expressing CXCR1. HL-60 cells expressing CXCR1 or CXCR2 loaded with Indo-1 were stimulated with 100 nM of CXCL8, CXCL1 or R6H-CXCL8 mutant. The percentages of intracellular calcium responses are estimated from the calcium signal elicited by permeabilization of the cells with the detergent dodecylmaltoside (referred as 100%). The record is representative of at least five independent experiments. doi:10.1371/journal.pone.0027967.g001
The CXCR1 N-terminus is the major determinant for binding selective CXCR1 agonists

We investigated whether the N-terminus of CXCR1 is essential for binding to R6H-CXCL8 and CC-CXCL8. We constructed a receptor chimera, in which the N-terminus of CXCR2 was replaced for the N-terminus of CXCR1. This chimera bound R6H-CXCL8 and CC-CXCL8 (Fig. 6). Interestingly this chimera failed to bind CXCL1. These findings are in good agreement with our previous studies with CXCR1/CXCR2 chimeras [15], in which the reciprocal exchange of N-termini switched the chemokine binding selectivity of the chimeric receptors. Moreover, we previously showed the important role of the CXCR1 N-terminus for binding to CXCL8 by transplanting the CXCR1 N-terminus into the mouse CXCR2, resulting in a mouse CXCR2 mutant exhibiting high affinity binding to CXCL8 [16].

Discussion

These novel chemokine derivatives (R6H-CXCL8 and CC-CXCL8) represent the first generation of CXCR1 agonists, which will aid in probing the functional significance of CXCR1 in vivo under pathophysiologial conditions, in particular in tissues co-expressing CXCR1, CXCR2 and DARC. In fact, we found that activation of human neutrophils, which co-express CXCR1 and CXCR2, with the newly engineered CXCR1 agonists desensitized the calcium responses mediated by CXCR2, but activation of CXCR2 did not desensitize the activation of CXCR1. This finding could have important implications in the regulation of inflammation, as CXCR1 agonists could operate as selective anti-
inflammatory agents by preventing the activation of CXCR2, which is responsible for the accumulation of neutrophils into inflamed tissues due to injury or infection [4]. Engineering selective CXCR1 antagonists will complement the studies with the CXCR1 agonists in further defining the significance of CXCR1 in pathophysiological conditions.

Importantly, these novel CXCR1 agonists are revealing for the first time the key structural elements in chemokines for the activation of CXCR1 and CXCR2, and compels to revise the current two-state model involving the interaction of chemokines with their cognate receptors. In this new model, the interactions of CXCL8 with CXCR1 and CXCR2 are different. On the basis of our data and previous studies [15,16,17,18] CXCL8 binds to CXCR1 according to the classical two-site model (Fig. 7a), in which the N-loop of CXCL8 interacts with a receptor site (Site 1) defined by the N-terminus of CXCR1, a major determinant for the selective binding to CXCL8 to CXCR1. Site2 in CXCR1 binds to Glu4 of CXCL8 to trigger receptor activation, without major contribution from Arg6 or the CXC motif. On the other hand, we propose a new model for the interaction of CXCL8 with CXCR2, in which CXCR2 binds to the N-terminus of CXCL8 (Glu4, Arg6 and CXC motif) to trigger receptor activation, without significant contributions of either the N-terminus of the receptor or the N-loop of CXCL8 (Fig. 7b), as demonstrated by the broad binding of CXCR2 to all ELR-CXC chemokines containing non-conserved residues in their N-loops [19], and by the studies showing that the CXCR2 chimera containing the non-related N-terminus of the chemokine receptor CCR1 is still activated by all ELR-chemokines [17]. Finally, DARC is a hybrid of CXCR1/CXCR2, the conserved ELR-CXC in chemokines is required for binding to DARC, but the N-terminus of DARC is required for its binding to multiple chemokines (ELR-CXC and CC chemokines), as the CXCR2 mutant containing the DARC N-terminus exhibits the same binding profile as wild type DARC [14].

Optimization of our CXCR1 agonists will help designing more potent CXCR1 agonists and antagonists, which can be used as inflammatory modulators for the treatment of life threatening inflammatory disorders.

Materials and Methods

Expression and Purification of CXCL8 Mutants
cDNA encoding the human CXCL8 (1–66) were cloned into the E.coli expression vector pET32-Xa-Lic, which is used as template for engineering CXCL8 mutants by site directed mutagenesis. The wild type CXCL8 and mutants were expressed in E.coli BL21 (DE3) pLys and purified by chromatography.
fractionation using a His trap column, followed by a Mono S column or reverse phase column as described [11]. Alternatively, CXCL8 and mutants were also expressed in Insect S2 cells, which secrete CXCL8 mutants into the culture media.

**Intracellular Ca$$^{2+}$$ Mobilization**

Human neutrophils were incubated with 5 μM Indo-1AM in Hank's solution without Ca$$^{2+}$$ and Mg$$^{2+}$$ at a density of ~10$$^7$$ cells/ml for 30 min at 37°C in the dark. HL60 cells expressing CXCR1 and CXCR2 were loaded as for neutrophils except that the cells were loaded with Indo-1 in RPMI. Subsequently, neutrophils and HL60 cells were washed with PBS and then resuspended in buffer containing 25 mM Hepes (pH 7.4), 125 mM NaCl, 5 mM KCl, 1 mM CaCl$$2$$, 0.5 mM MgCl$$2$$, 1 mM Na$$2$$HPO$$4$$, 0.1% bovine serum albumin, 0.1% glucose at a density of 10$$^7$$ cells/ml. We employed 10$$^6$$ cells/ml to record intracellular calcium in RF5301PC spectrofluorometer (Shimadzu), using an excitation wavelength of 330 nm and an emission wavelength of 405 nm, as described [20].

**125I-CXCL8 and 125I-CXCL1 Binding**

HL-60 cells (2×10$$^7$$ cells/ml) expressing CXCR1 or CXCR2 or ghost membranes (75 μg of protein/ml) from human red blood cells were incubated at 4°C for 4–6 h in PBS supplemented with 0.1% (w/v) bovine serum albumin and 20 mM HEPES (pH 7.4), 125I-CXCL8 and 125I-CXCL1, in the absence and presence of unlabeled CXCL8 or CXCL8 mutants. The binding reaction for HL60 cells was terminated by centrifugation at 200$$^6$$ g for 5 min over a 10% sucrose cushion. The binding reaction for ghost membranes was terminated as for binding to HL60 cells, except that the centrifugation was carried out at 13,000$$^6$$ g for 5 min. The cell or membrane pellets were counted in a c-counter.

**Internalization of CXCR1 and CXCR2.**

cDNA encoding CXCR1 or CXCR2 were cloned in frame to EGFP in the mammalian expression vector pEGFP-N1. HEK 293 cells (150,000 cells) grown in glass cover slips coated with poly L-lysine (0.01%) were transiently transfected with the plasmids (1 μg DNA) encoding the chimeric receptors, by using Fugene-6. After 48 h the transfected cells were treated with CXCL8 or CXCL8 mutants for 30 min at 37°C, then the cells were fixed with methanol at −20°C for 45 min and stained with DAPI. The fluorescence was recorded by using a confocal microscope (Bio Rad Radiance 2100).

**Expression of CXCR1 and CXCR2.**

HL-60 expressing CXCR1 and CXCR2 were engineered as described [11]. The NR1/CR2 mutant cDNA encoded the transplantation of the N-terminus of CXCR1 into CXCR2 was constructed according to [15]. COS-7 cells (150,000 cells) grown in glass cover slips coated with poly L-lysine (0.01%) were transiently transfected with the plasmids (1 μg DNA) encoding the chimeric receptors, by using Fugene-6. After 48 h the transiently transfected cells were treated with 125I-CXCL8 or CXCL8 mutants for 30 min at 37°C, then the cells were fixed with methanol at −20°C for 45 min and stained with DAPI. The fluorescence was recorded by using a confocal microscope (Bio Rad Radiance 2100).

**Rabbit skin inflammation.**

New Zealand rabbits (3–4 Kg) were maintained in the Animal Facility of the Universidad Peruana Cayetano Heredia (UPCH). Chemokine derivatives were injected into the shaved dorsal skin of rabbits, as described [21]. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Ethics Committee for Animal Use (CIAE) of the Universidad Peruana Cayetano Heredia (Permit SIDISI 58343).

**Supporting Information**

Figure S1 The mutants R6X-CXCL8 triggered calcium responses in HL-60 cells expressing CXCR1. HL-60 cells...
expressing CXCR1 or CXCR2 loaded with Indo-1 were stimulated with 1 μM R6X-CXCL8 mutants. The percentages of intracellular calcium responses are estimated from the calcium signal elicited by permeabilization of the cells with the detergent dodecylmaltoside (referred as 100%). The record is representative of at least five independent experiments.

**References**

1. Sallusto F, Baggiolini M (2000) Chemokines and leukocyte traffic. Nat Immunol 9: 949-952.
2. Clore GM, Gronenborn AM (1995) Three-dimensional structures of alpha and beta chemokines. FASEB J 9: 57-62.
3. Matlovic S, Nanney LB, Yu Y, White JR, Richmond A (2003) Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen 11: 213-219.
4. White JR, Lee JM, Young PR, Hertzberg RP, Jurwicz AJ, et al. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273: 10095-10098.
5. Lee J, Cacalano G, Camerato T, Toy K, Moore MW, et al. (1995) Chemokine binding and activities mediated by the mouse IL-8 receptor. J Immunol 155: 2158-2164.
6. Hart D, Latunin P, Hordijk P, Marcos V, Rudolph C, et al. (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cytic fibrosis lung disease. Nat Med 13: 1423-1430.
7. Ragnarsdottir B, Fischer H, Godaly G, Gronberg-Hernandez J, Gustafsson M, et al. (2008) TRK- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 38 Suppl 2: 12-20.
8. Rajagopalan L, Rajarathnam K (2006) Structural basis of chemokine receptor function—a model for binding affinity and ligand selectivity. Biosci Rep 26: 325-339.
9. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M (1993) Platelet factor 4 binds to interleukin-8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A 90: 3574-3577.
10. Kramer S, Lee H, Zernecke A, Kaparniost A, Andreotto E, et al. (2011) MIP-1α: chemokine receptor interactions in atherosclerosis are dependent on an N3-loop-based 2-site binding mechanism. FASEB J 25: 894-906.
11. Joseph PR, Sarmiento JM, Misra AK, Das ST, Garafalo RP, et al. (2010) Probing the role of CXCR7 motif in chemokine CXCL12 for high affinity binding and activation of CXCR1 and CXCR2 receptors. J Biol Chem 285: 29262-29269.
12. Prado GN, Thomas KM, Suzuki H, LaRosa GJ, Wilkinson N, et al. (1994) Molecular characterization of a novel rabbit interleukin-8 receptor isotype. J Biol Chem 269: 12391-12394.
13. Catrusse J, Struyf S, Wuyts A, Weyer M, Loos T, et al. (2004) Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6. Biochim Pharmacol 68: 1947-1955.
14. Lu ZH, Wang ZX, Horuk R, Hesselgesser J, Lou YC, et al. (1995) The promiscuous chemokine binding profile of the Duffy antigen/receptor for chemokines is primarily localized to sequences in the amino-terminal domain. J Biol Chem 270: 26292-26295.
15. LaRosa GJ, Thomas KM, Kaufmann ME, Mark R, White M, et al. (1992) Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. J Biol Chem 276: 25492-25496.
16. Suzuki H, Prado GN, Wilkinson N, Navarro J (1994) The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8. J Biol Chem 269: 18263–18266.

17. Ahuja SK, Lee JC, Murphy PM (1996) CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem 271: 225–232.

18. Lowman HB, Slagle PH, DeForge LE, Wirth CM, Gillece-Castro BL, et al. (1996) Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities. J Biol Chem 271: 14344–14352.

19. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392: 563–568.

20. Suetomi K, Lu Z, Heck T, Wood TG, Prusak DJ, et al. (1999) Differential mechanisms of recognition and activation of interleukin-8 receptor subtypes. J Biol Chem 274: 11768–11772.

21. Forrest MJ, Jose PJ, Williams TJ (1986) Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation of the rabbit peritoneal cavity. Br J Pharmacol 89: 719–730.